The '1-Minute' Cancer Jab Now Available in the UK When Will Africa Get It?

A landmark moment in cancer treatment was announced today, May 4, 2026, as the NHS in England rolled out a revolutionary injectable form of one of the world's most powerful cancer immunotherapy drugs. For patients in wealthy nations, it is a game-changer. For Africa which carries one of the heaviest cancer burdens on the planet the question is how long the wait will be.

The Breakthrough: A Jab in 60 Seconds
The NHS is rolling out a new injectable form of pembrolizumab widely known by its brand name Keytruda which can slash the time the treatment takes by up to 90%, helping patients spend less time in hospital while improving NHS productivity. The jab can be used to treat 14 different cancer types, including lung, breast, head and neck, and cervical cancer. It works by triggering immune cells to recognize and kill cancer cells.

Around 14,000 patients start pembrolizumab therapy each year in England, and most are now expected to benefit from the more convenient treatment. The new under-the-skin injection replaces an intravenous infusion that can take up to two hours in total per session. The treatment will be given every three weeks as a one-minute injection, or every six weeks as a two-minute injection, depending on cancer type.

One of the first patients to receive the new injection 89-year-old Shirley Xerxes from St Albans hailed it as "unbelievable" to be in the treatment chair for just a "matter of minutes", giving her "more time to live her life."

What Is Pembrolizumab?
Pembrolizumab is a humanized monoclonal antibody specifically a PD-1 inhibitor — used in cancer immunotherapy to treat many types of cancer. It targets the programmed cell death protein 1 (PD-1) receptor of lymphocytes. It was approved for medical use in the United States in 2014 and is on the World Health Organization's List of Essential Medicines.

In simple terms, the drug removes the "brakes" that cancer cells use to shield themselves from the immune system freeing the body's own defenses to identify and destroy tumors.

The African Reality: A Cancer Crisis Already Unfolding

While the NHS celebrates this innovation, Africa faces a deepening cancer emergency.

There were over 800,000 new cancer cases and more than 520,000 deaths in sub-Saharan Africa in 2020, and experts predict a doubling of this incidence and mortality by 2040 without appropriate intervention meaning over one million lives lost to cancer in sub-Saharan Africa in 2040 alone. Cancer deaths in sub-Saharan Africa have already exceeded the combined death rates of malaria, tuberculosis, and AIDS.

In sub-Saharan Africa, up to 70% of cancer patients present with advanced stage cancer precisely the situations where immunotherapy like pembrolizumab is most needed, yet least available.

Is Pembrolizumab Available in Africa at All?

The IV drip form of pembrolizumab does exist in some African countries, but access is extremely limited. While the price of Keytruda per vial is four to five times less expensive in African countries compared to US prices, the cost of each vial is still thousands of dollars a prohibitive barrier for most patients and health systems on the continent.

Immunotherapy utilization and training is low in sub-Saharan Africa and insufficient for the rising cancer burden. Increased accessibility and usage of biomarker testing to predict immunotherapy response, incorporation of immunotherapy training into medical education, and increased access to immunotherapy drugs are prerequisites for expanded utilization of immunotherapy in the region.

When Could the Injectable Form Reach Africa?

No timeline has been announced by manufacturer MSD (Merck) for rolling out the subcutaneous injectable form of pembrolizumab across Africa. Based on the historical pattern of drug access on the continent, experts and observers expect a significant lag potentially of many years for several reasons.

Regulatory approvals must be obtained from individual national medicines agencies or regional bodies such as the African Medicines Agency (AMA), which is still in its formative stages. Supply chain infrastructure, cold storage requirements, trained oncology staff, and the sheer cost of the drug all present further hurdles.

The IV version of pembrolizumab was approved in the US in 2014 and has still not achieved widespread access across most of Africa more than a decade later. Unless accompanied by a specific access programme, negotiated pricing, or inclusion in donor-supported cancer initiatives, the injectable version is unlikely to reach the majority of African patients in the near term.

The Equity Question
The contrast could hardly be starker. In England today, a cancer patient can walk into a clinic, receive a life-saving immunotherapy jab in 60 seconds, and go home. In Lagos, Accra, Nairobi, or Dakar, most cancer patients still present when disease is already advanced, often without access to any form of immunotherapy at all.

For Africa, the arrival of this injectable breakthrough in the UK is both an inspiring scientific milestone and a sobering reminder of how wide the global health equity gap remains.

Mustapha Bature Sallama.
Medical/ Science Communicator,
Private Investigator, Criminal investigation and Intelligence Analysis.

International Conflict Management and Peace Building.USIP

mustysallama@gmail.com
+233-555-275-880

   Comments0